Vision Loss News and Research

RSS

Acute glaucoma is largely an inflammatory disease, say researchers

Researchers at the University of California, San Diego School of Medicine and Sun Yat-sen University in China have shown that acute glaucoma in mice is largely an inflammatory disease and that high pressure in the eye causes vision loss by setting in motion an inflammatory response similar to that evoked by bacterial infections.

14 Jul 2014

BrightFocus offers grants to 55 scientists for Alzheimer's disease and vision research

BrightFocus Foundation, a nonprofit organization funding cutting-edge, innovative research on Alzheimer's disease and the vision diseases of glaucoma and macular degeneration, today announced the recipients of new research grant awards, offered to 55 scientists in 19 U.S. states, the District of Columbia, and five foreign countries.

11 Jul 2014

Poor printing on prescription labels may lead to errors in taking medication

Small print and poor printing on prescription labels handed out by pharmacists may be misread and may lead to errors in taking medication, according to new research by the University of Waterloo and CNIB (Canadian National Institute for the Blind).

11 Jul 2014

New approach for developing personalized gene therapies to treat retinitis pigmentosa

Columbia University Medical Center researchers have created a way to develop personalized gene therapies for patients with retinitis pigmentosa (RP), a leading cause of vision loss.

11 Jul 2014

Integrated therapies can reduce depression by half among people with low vision due to AMD

The first clinical trial to examine integrated low vision and mental health treatment has shown that the approach can reduce the incidence of depression by half among people with low vision due to age-related macular degeneration (AMD).

9 Jul 2014

New approach can reduce depression in patients with AMD-related low vision

Depression is a common risk for people who have lost their vision from age-related macular degeneration (AMD), but a new study shows that a type of rehabilitation therapy can cut this risk in half. The study was funded by the National Eye Institute (NEI), part of the National Institutes of Health.

9 Jul 2014

Researchers find unique cell type that can protect against uveitis

Researchers at the National Eye Institute (NEI) have found a unique cell type that, in tests on mice, can protect against uveitis—a group of inflammatory diseases that affect the eye and can cause vision loss.

1 Jul 2014

American Academy of Ophthalmology does not recommend marijuana for glaucoma treatment

The American Academy of Ophthalmology – the world's largest association of eye physicians and surgeons – is reminding the public that it does not recommend marijuana or other cannabis products for the treatment of glaucoma.

28 Jun 2014

Telemedicine is effective strategy to screen for potentially blinding disease in infants

Telemedicine is an effective strategy to screen for the potentially blinding disease known as retinopathy of prematurity (ROP), according to a study funded by the National Eye Institute (NEI).

27 Jun 2014

Low-power sensor to track changes in eye pressure for management of glaucoma

Your eye could someday house its own high-tech information center, tracking important changes and letting you know when it's time to see an eye doctor.

17 Jun 2014

UAB ophthalmologists offer tips to prevent firework related injuries

Fourth of July 2013: Family members were shooting fireworks in the backyard of Dianne Peterson's home in Vincent, Alabama, as she walked out of the house.

9 Jun 2014

Study: The brain controls cellular process that leads to glaucoma

Findings from a new study published in Translational Vision Science & Technology show the brain, not the eye, controls the cellular process that leads to glaucoma. The results may help develop treatments for one of the world's leading causes of irreversible blindness, as well as contribute to the development of future therapies for preserving brain function in other age-related disorders like Alzheimer's.

6 Jun 2014

RPB grants $500,000 to accelerate treatments for Retinitis Pigmentosa

Research to Prevent Blindness (RPB), the leading eye research foundation, is providing $500,000 to accelerate the development of treatments for Retinitis Pigmentosa (RP) -- a family of retinal diseases that progressively create extreme tunnel vision, loss of night vision and leave affected patients legally blind by the age of 40.

5 Jun 2014

CenterVue's next generation Macular Integrity Assessment receives FDA clearance

CenterVue, Inc., a leader in the design and manufacture of highly automated medical devices for the diagnosis and management of ocular pathologies, today announced FDA 510(k) clearance has been granted for the company's next generation Macular Integrity Assessment (MAIA).

4 Jun 2014

Study shows high BP drugs may raise likelihood of age-related macular degeneration

There may be a connection between taking vasodilators and developing early-stage age-related macular degeneration (AMD), the leading cause of vision loss and blindness among Americans who are age 65 and older, according to a study published online in Ophthalmology, the journal of the American Academy of Ophthalmology.

29 May 2014

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

AbbVie announced today that the U.S. Food and Drug Administration has granted HUMIRA orphan drug designation for the treatment of non-infectious intermediate, posterior, or pan-uveitis, or chronic non-infectious anterior uveitis, a group of rare but serious inflammatory diseases of the eye.

21 May 2014

Amakem commences Phase 2 dose-ranging study of AMA0076 drug for treatment of glaucoma

Amakem Therapeutics, a clinical stage ophthalmology company, today announced that first patients have commenced treatment in a Phase 2 dose-ranging study of its lead drug candidate, AMA0076 for the treatment of glaucoma.

13 May 2014

New drug approach for safer clean-up of deformed blood vessels in eye

A new drug approach has been developed for safer clean-up of deformed blood vessels in the eye by a research team at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital in Toronto.

12 May 2014

First reversible glue to treat eye injuries of soldiers

Scientists have developed the first reversible glue that could be used on the battlefield to treat eye injuries, potentially saving soldiers' vision. The research is being presented at the 2014 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) this week in Orlando, Fla.

7 May 2014

Monthly injections to counteract AMD may not be necessary, say researchers

Researchers have found that, contrary to prvious clinical trial findings, monthly injections to counteract age-related macular degeneration (AMD) may not be necessary.

7 May 2014

Vision Loss News and Research

Acute glaucoma is largely an inflammatory disease, say researchers

BrightFocus offers grants to 55 scientists for Alzheimer's disease and vision research

Poor printing on prescription labels may lead to errors in taking medication

New approach for developing personalized gene therapies to treat retinitis pigmentosa

Integrated therapies can reduce depression by half among people with low vision due to AMD

New approach can reduce depression in patients with AMD-related low vision

Researchers find unique cell type that can protect against uveitis

American Academy of Ophthalmology does not recommend marijuana for glaucoma treatment

Telemedicine is effective strategy to screen for potentially blinding disease in infants

Low-power sensor to track changes in eye pressure for management of glaucoma

UAB ophthalmologists offer tips to prevent firework related injuries

Study: The brain controls cellular process that leads to glaucoma

RPB grants $500,000 to accelerate treatments for Retinitis Pigmentosa

CenterVue's next generation Macular Integrity Assessment receives FDA clearance

Study shows high BP drugs may raise likelihood of age-related macular degeneration

AbbVie receives HUMIRA orphan drug designation from FDA for treatment of non-infectious uveitis

Amakem commences Phase 2 dose-ranging study of AMA0076 drug for treatment of glaucoma

New drug approach for safer clean-up of deformed blood vessels in eye

First reversible glue to treat eye injuries of soldiers

Monthly injections to counteract AMD may not be necessary, say researchers

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News